very year, clinical trial sponsors spend an estimated 20% of a study budget on monitoring activities, a significant portion of which exists to reconcile what was documented in a paper binder with what ultimately lives in the electronic data capture (EDC) system. The data was already captured. It was already reviewed and signed by a clinician. Yet the industry has built an entire infrastructure dedicated to transcribing it again, checking it again, and resolving discrepancies that should never have existed in the first place.

This is not a technology problem. It is a coordination problem that technology can now solve, if sponsors, sites, contract research organizations (CROs), and vendors agree to behave differently. The path forward is called central eSource, a model in which data captured at the site becomes the source of record and flows directly into the EDC with no intermediate transcription step. It exists today. Sites are running it in production. The question is no longer whether it works. The question is why industry is still so slow to adopt it.

Why Has the Conversation Changed?

Site source—the documentation of clinical trial data at the point of care—has been a persistent friction point in drug development for decades. Paper source documents, followed by parallel electronic systems that still required manual transcription into sponsor EDCs, created a workflow that is simultaneously labor-intensive for sites and expensive for sponsors to monitor.

What is different today is the convergence of three forces. First, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have clarified that electronic records generated at the site can serve as the primary source, removing a long-standing ambiguity that made sponsors cautious about accepting anything other than paper. Second, the technology infrastructure, site-side platforms, EDC integration standards, and connectivity between systems have matured enough to make seamless data flow operationally realistic. Third, and perhaps most importantly, sponsors are under more pressure than ever to reduce trial timelines and per-patient costs. The administrative overhead embedded in traditional source-to-database workflows has become a visible target.

A panel of study site operators, CRO leaders, and technology vendors mapped the terrain of this transition, not as a future-state aspiration but as a present-day operational reality with a clear set of remaining barriers, at the DIA 2026 Global Annual Meeting session “Reimagining Site Source.” The crowd, and the questions that kept coming throughout, were a signal in themselves: Industry knows something needs to change, and it is actively looking for the path forward.

What Central eSource Actually Changes

The operational impact of central eSource, where a site uses a single, sponsor-agnostic platform to capture source data that is then mapped directly to the EDC system, is most visible at the site-coordinator level. Under the traditional model, a site coordinator documents an assessment in a paper chart or site-specific electronic record, then re-enters that data into a sponsor-provided EDC. When queries are generated, the coordinator must reconcile two records that should have been one in the first place. This dual-entry workflow, repeated across every data point in every visit across every active study, is where coordinators spend their time and where transcription errors often occur.

Sites that have moved to central eSource report measurable reductions in query rates and in the time required to resolve the queries that do arise. These examples include a 70% reduction in query tracking and a 32% reduction in coordinator time. More importantly, they report that coordinators spend more time with patients and less time with keyboards. For a site running 10 to 20 concurrent studies, the cumulative effect on capacity is significant. The data does not have to be re-entered because it was never separated from the source in the first place.

For sponsors and CROs, the implications are equally direct. Remote monitoring becomes more meaningful when the data available remotely is the same data the site generated rather than a downstream copy that may have already introduced transcription error. Source data verification (SDV) rates, still mandated at 100% in many sponsor protocols despite a decade of risk-based monitoring guidance from, for example, the FDA and EMA, become less justifiable when the source and the EDC are the same record.

What makes this model work in practice, and what became clear in the DIA discussion, is the balance between standardization and site autonomy. Sponsors can equip sites with a protocol-driven template that defines the data required for a given study yet still give sites the ability to add procedures and configurations specific to their workflows. A site coordinator may have established processes that predate any given sponsor relationship. Those processes represent institutional knowledge, refined over years of study execution. A central eSource model that forces sites to abandon institutional knowledge in favor of rigid sponsor templates will fail. However, a model that treats the sponsor template as a foundation rather than a ceiling, and preserves space for site-specific documentation alongside it, creates something more powerful: a record that meets sponsor data requirements while reflecting how care is delivered at that site. The combination of those two layers is where central eSource becomes a durable infrastructure investment instead of just another point-of-problem solution.

The Four-Party Alignment Problem

The gap between what central eSource can deliver and what the industry has adopted reflects a coordination challenge more than a technology challenge. Making site source work at scale requires four parties to change behavior simultaneously: sites, sponsors, CROs, and technology vendors.

Sites have legitimate concerns. Every sponsor-driven technology mandate they have accepted over the past 15 years has added to a stack of point-solutions they are responsible for training on, maintaining, and switching from study to study. The ask embedded in central eSource—adopt a platform that works across your entire study portfolio, not just for one sponsor—is fundamentally different from previous mandates, but sites have no guarantee that sponsors will honor it. The site that invests in an eSource infrastructure still risks being told by a new sponsor that they must use a different system.

Sponsors, for their part, have written EDC and data management requirements into contracts and requests for proposals that assume traditional source-to-EDC transcription. Changing those requirements calls for agreement across clinical operations, data management, and regulatory functions, and often requires renegotiating language with CRO partners as well. The path of least resistance is to leave the language as is.

CROs sit in the operational middle. They are responsible for delivering sponsor mandates across global site networks, and they carry the monitoring cost that central eSource would reduce. They also carry the contractual and change-management risk of asking sponsors to accept a different monitoring model. The financial incentive for CROs to advocate loudly for a model that reduces billable monitoring hours is not straightforward.

Technology vendors have historically built platforms with proprietary data models that make interoperability a commercial negotiation rather than a technical default. Until integration between site-side eSource platforms and EDC systems is treated by the industry as a standard way of conducting research at the site rather than as a billable integration project, the friction lives in the technology layer even when the parties are aligned in principle.

What Each Party Must Do Differently

The path to scale is not complicated in concept, though it is significant in execution. Each party in the four-party model has a concrete role:

• Sites must evaluate central eSource platforms not study by study, but as a portfolio infrastructure investment, selecting a platform that can serve as their system of record across all active studies, regardless of sponsor.
• Sponsors must write protocol and data-management specifications that describe the data they require, not the workflow by which they expect to receive it. Workflow-neutral specifications allow sites to use the technology that works for them while still meeting sponsor data requirements.
• CROs must reframe what monitoring means when source and EDC are unified. Risk-based monitoring, already endorsed by the FDA and EMA, becomes far more operationally tractable when query rates fall and remote data access improves.
• Vendors must treat interoperability as a baseline, not a differentiator. Proprietary integration paths that require bilateral agreements for every sponsor-EDC-eSource combination will not scale. Industry-wide adoption of common data exchange standards, such as Clinical Data Interchange Standards Consortium (CDISC) models, is the prerequisite for the rest of the model to function.

The Patient at the Center

The efficiency arguments for reimagining site source are compelling on their own. But the more durable argument is patient-centered. Every minute a coordinator spends reconciling two records of the same data is a minute not spent with a patient. Every unnecessary site visit driven by SDV requirements adds to the participant burden that already makes clinical trial retention a persistent challenge.

Cleaner data at the source also means faster and more reliable safety signals. When the data that reaches a sponsor’s safety team has been transcribed, reconciled, and queried along the way, delays (and possibly errors) are embedded in the process. The time from safety event occurrence to detection shrinks when the source record and the database record are the same—and in oncology or rare-disease studies where adverse event detection is time-sensitive, that matters.

The decentralized and hybrid trial models accelerated by the COVID-19 pandemic depend on the same foundational shift. A patient who participates in a hybrid study—some visits at a site, some at home through wearables or telehealth—generates source data across multiple touchpoints. A traditional paper-based or site-siloed source model cannot capture that data cleanly. Central eSource, by treating the platform rather than the location as the source of record, creates the foundation that hybrid trial designs require.

The Time to Move Is Now

The industry has had the regulatory clarity, technology, and clinical logic to move on central eSource for several years. What it has lacked is the coordinated will of sponsors, sites, CROs, and vendors acting in aligned self-interest rather than sequential caution.

The sites that have committed to central eSource are not waiting for permission. They are running studies, building institutional knowledge, and developing coordinator workflows that work. The sponsors and CROs that recognize this are beginning to write contract language that accommodates it. The vendors that treat interoperability as a strategic imperative rather than a competitive threat are beginning to build toward it.

“Don’t get hung up on perfection.”

One of the moments from the DIA session that stuck with many in the room came from a panelist who offered a simple reframe. To summarize: Don’t get hung up on perfection. Industry has a tendency to delay adoption until every edge case is resolved, every integration is mapped, and every workflow is validated. The only way to move the bar forward is to start: to take the step, run the study, and build the institutional knowledge that comes from doing. The model does not need to be perfect to be better than what it replaces. And what it replaces has warts of its own, most of them invisible because they have been normalized over decades.

The other thread that ran through the post-session conversations was the burden side of the equation. Sites are stretched. The complexity of clinical trials keeps rising—more endpoints, more data points, more regulatory requirements per protocol—and the coordinator workforce has not scaled to match. Anything that reduces administrative overhead and returns time to the work of recruiting, retaining, and caring for participants is not a luxury. It is a survival mechanism. That is the argument for central eSource that does not require a spreadsheet: sites that can run more studies with the same team, at the same quality, are the sites that stay in business and keep serving patients.

The friction that slows clinical trials today is not a feature of the work. It is an artifact of a data infrastructure designed for a paper world that no longer exists. Reimagining site source is not a disruption of clinical research, it is a return to the principle that data should serve the trial, not the other way around.